Concepedia
Statistics
Publications
28
Citations
2.2K
H-Index
21
Active since
1998
Affiliations
Pfizer (United States)(Current)
Michigan State University
Ono Pharmaceutical (United States)
Merck KGaA, Darmstadt (Germany)
Research & Development Institute
Igor Mochalkin is an author at Pfizer (United States) specializing in medicinal chemistry, drug discovery, and pharmacy.
Publications per year
1998–2021
Large-Scale Assessment of Binding Free Energy Calculations in Active Drug Discovery Projects
Christina Schindler, Hannah M. Baumann, Andreas Blum et al. · Journal of Chemical Information and Modeling · 2020 · 311 citations
Pharmacy, Chemistry, Medicinal Chemistry +14
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text
Medicine, Cancer Biology, Oncology +16
A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides
Zhe Yang, Igor Mochalkin, Russell F. Doolittle · Proceedings of the National Academy of Sciences · 2000 · 203 citations · Full text
Life Sciences, Biochemistry, Biophysics +17
Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen, Youyan Zhang, Robert D. Van Horn et al. · Cancer Discovery · 2016 · 172 citations
Life Sciences, Molecular Biology, Oncology +15
A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore
J. Richard Miller, Steve Dunham, Igor Mochalkin et al. · Proceedings of the National Academy of Sciences · 2009 · 160 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +17
1–5 of 28